Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT)

SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the securities laws. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders. Corcept's drug Korylm is a cortisol receptor blocker used to control hyperglycemia.

If you would like more information about Corcept Therapeutics Incorporated's misconduct, click here.

Corcept Therapeutics Incorporated (CORT) is Being Investigated for Illicit Sales Practices

On December 8, 2021, Corcept disclosed that "[o]n November 15, 2021, the Company received a records subpoena from the U.S. Attorney's Office for the District of New Jersey (the 'NJ USAO') pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPPA) seeking information relating to the sale and promotion of Korlym, Corcept's relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym." The Company further disclosed that "[t]he NJ USAO has informed Corcept that it is investigating whether any criminal or civil violations by Corcept occurred in connection with the matters referenced in the subpoena."

On this news, Corcept's stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.

Corcept Therapeutics Incorporated (CORT) shareholders have legal options. If you own shares of Corcept Therapeutics Incorporated, contact us to learn more about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Corcept Therapeutics Incorporated settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:CORT

Release Summary

Corcept Therapeutics Incorporated (CORT) is Being Investigated for Illicit Sales Practices

Release Versions

$Cashtags

Hashtags

#securitiesviolations

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more information, submi...

ARDT Class Action Reminder: Stockholders Who Lost Money Investing in Ardent Health, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2025 and November 12, 2025. Ardent Health and its affiliates operate acute care hospitals and other healthcare facilities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? Robbins LLP is Investigating...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the NuScale Power Corporation Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired NuScale Power Corporation (NYSE: SMR) Class A shares between May 13, 2025 and November 6, 2025. NuScale is a nuclear technology company focused on scalable, modular reactors. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that...

Back to Newsroom